Austin-Headquartered Neurotech Maverick Reflects Upon Industry, Company Growth
NEW YORK, Oct. 8, 2025 /PRNewswire/ — Dr. Connor Glass, CEO and Founder of Phantom Neuro, the company delivering breakthrough advancements in human-machine interface, will be speaking on the mainstage of this year’s BioFuture™ 2025. The conference is hosted by Demy-Colton and held in New York City this October 13th through 15th.
The innovative healthcare startup will be on stage among the likes of biotech, pharma, digital medicine, TechBio, healthcare delivery, policy, and investment leaders, participating in an industry-wide discussion of how new policy, technology, and capital markets are reshaping the healthcare ecosystem. Events will be held at Cure, a Deerfield affiliate in health and life science innovation.
Dr. Connor Glass
, CEO and founder Phantom Neuro, will present during a Spotlight Panel, “
Rewiring Minds: Breakthroughs in Brain & CNS Health” (Spotlight Panel 1B). More information:
The panel will be moderated by Ginger Johnson, Senior Vice President, Lumanity. The panel includes:
This year has shown robust and continued growth for Phantom Neuro, from the company receiving FDA Breakthrough Device and TAP Designations to announcing additional funding and a new strategic partner in European medical and industrial robotic technologies company, Ottobock.
More recently, Phantom Neuro published a peer-reviewed white paper detailing findings from the startup’s proprietary Phantom X platform. This study demonstrates intuitive and functional prosthesis control designed for real-world use.
ABOUT PHANTOM NEURO
Phantom Neuro is a neurotechnology company developing a minimally invasive interface that enables intuitive control of prosthetic limbs and robotic exoskeletons. Originally developed at the Johns Hopkins University School of Medicine, Phantom Neuro has received funding from investors including Ottobock, Blackrock Neurotech, Breakout Ventures, Draper Associates, LionBird Ventures, and Time BioVentures. Headquartered in Austin, Texas, Phantom Neuro is backed by a globally recognized advisory board of experts from CTRL-Labs, D.A.R.P.A., Johns Hopkins University, and Precision Neuro. Learn more at www.phantomneuro.com.
CONTACT:
Shannon Wilsey, Public Relations | Phantom Neuro
info@phantomneuro.com
SOURCE Phantom Neuro Inc.
Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…
PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…
IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…
CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…
The Life Sciences BPO Market is expanding rapidly, driven by rising R&D costs, increasing regulatory…
Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…